About this trial

Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.

The objective of this study is to evaluate the impact of mobile venous thromboembolism application (mVTEA) based patient-centered management of pulmonary thromboembolism (PTE) on the long-term outcome of PTE patients, in order to enhance clinical practice and establish a foundation of evidence for managing patients with PTE.

Eligibility criteria

Qualifiers

Inpatients aged ≥18 years;

(2)PTE confirmed through imaging examinations, meeting at least one of the following criteria: a.Newly diagnosed PTE during the current hospitalization; b. Prior PTE with imaging evidence of residual thrombus.

Signed informed consent.

Disqualifiers

Previous PTE combined with CTEPH;

Mental retardation or a combination of other serious illnesses that make them incapable of living on their own;

Inability to use smartphones, computer tablets and other smart devices;

Being pregnant or breastfeeding;

Trial design

Treatments tested in this trial

  • mobile venous thromboembolism application (mVTEA)

Treatment groups

2,972 Participants
are divided into 2 treatment groups

Locations

1
Sixth Medical Center of Chinese PLA General Hospital100048, BeijingBeijing Municipality, China

Sponsors and collaborators

Navy General Hospital, Beijing

Lead sponsor